Health
Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19 – Loma Linda University Health
ACTIV-2 is studying multiple early COVID-19 treatments
Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19.Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…
-
Business23 hours agoWhere will Berkshire Hathaway be in 1 year?
-
Noosa News18 hours agoTwo trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business19 hours agoUp 105% in a year, are Pro Medicus shares still a good buy today?
-
Business17 hours agoEverything you need to know about the Coles dividend